nivolumab/relatlimab/hyaluronidase (BMS-986213/rHuPH20)
/ BMS, Halozyme
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
March 06, 2025
RELATIVITY-127: A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma
(clinicaltrials.gov)
- P3 | N=570 | Active, not recruiting | Sponsor: Bristol-Myers Squibb | Recruiting ➔ Active, not recruiting | Trial completion date: Aug 2025 ➔ Nov 2027
Enrollment closed • Trial completion date • Melanoma • Oncology • Solid Tumor
December 04, 2024
RELATIVITY-127: A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma
(clinicaltrials.gov)
- P3 | N=570 | Recruiting | Sponsor: Bristol-Myers Squibb | Trial completion date: Feb 2025 ➔ Aug 2025 | Trial primary completion date: Feb 2025 ➔ Aug 2025
Metastases • Trial completion date • Trial primary completion date • Melanoma • Oncology • Solid Tumor
1 to 2
Of
2
Go to page
1